Research programme: cytokine receptor modulators - Zymeworks
Latest Information Update: 28 Jan 2026
At a glance
- Originator Zymeworks
- Class Anti-inflammatories; Bispecific antibodies
- Mechanism of Action Cytokine receptor modulators; Immunomodulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation
Most Recent Events
- 28 Jan 2026 No recent reports of development identified for preclinical development in Autoimmune-disorders in Canada (Parenteral)
- 28 Jan 2026 No recent reports of development identified for preclinical development in Inflammation in Canada (Parenteral)
- 14 Dec 2021 Cytokine receptor modulators - Zymeworks is available for licensing as of 14 Dec 2021. https://www.zymeworks.com/contact